Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor
• * Locally advanced or metastatic disease
• Disease progressed on or after standard therapy OR there is no standard therapy for the malignancy
• * Standard therapy is defined as first- or second-line therapy that has been shown to provide clinical benefit
• Life-long non-smoker
• No lung metastasis and/or pleural effusion causing signs or symptoms that impact patient performance status
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Body mass index ≤ 35
• No concurrent uncontrolled illness including, but not limited to, the following:
• * Ongoing or active infection
• * Symptomatic congestive heart failure
• * Unstable angina pectoris
• * Ventricular arrhythmia
• * Psychiatric illness or social situation that would limit compliance with study requirements
• No uncontrolled chest or abdominal pain
• No oral or facial pain exacerbated by an oral device
• No stress incontinence
• No COPD, interstitial lung disease, pulmonary embolism, or hemorrhage within the past 6 months
• No history of pulmonary fibrosis or pulmonary hypertension
• No oxygen requirement at baseline
• No asthma
• No occupational lung disease, including, but not limited to, asbestos exposure
• No polycythemia
• No history of connective tissue disease
• PRIOR CONCURRENT THERAPY:
• No prior radiotherapy to the lung
• At least 6 months since prior lung surgery
• No prior amiodarone hydrochloride
• No prior high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation
• No concurrent combination antiretroviral therapy for HIV-positive patients